Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
83.72
-0.18 (-0.21%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $10.73M in the quarter ending March 31, 2026, with 2,873.41% growth. This brings the company's revenue in the last twelve months to $1.17M, up 194.24% year-over-year. In the year 2025, Crinetics Pharmaceuticals had annual revenue of $7.70M with 640.71% growth.
Revenue (ttm)
$1.17M
Revenue Growth
+194.24%
P/S Ratio
488.54
Revenue / Employee
$30,419
Employees
594
Market Cap
8.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 6.66M | 640.71% |
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
| Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
| Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
| Dec 31, 2016 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Ionis Pharmaceuticals | 1.06B |
| Corcept Therapeutics | 769.10M |
| Krystal Biotech | 417.30M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Praxis Precision Medicines | 7.46M |
CRNX News
- 1 day ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI) - GlobeNewsWire
- 1 day ago - Crinetics Pharmaceuticals Proxy statement: Proxy filing - Filings
- 2 days ago - Crinetics Pharmaceuticals Slides: Corporate presentation - Filings
- 12 days ago - Crinetics Pharmaceuticals Proxy statement: Proxy filing - Filings
- 14 days ago - Crinetics downgraded to Hold from Buy at Stifel - TheFly
- 15 days ago - How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks - Barrons
- 15 days ago - Crinetics downgraded to In Line from Outperform at Evercore ISI - TheFly
- 15 days ago - Crinetics downgraded to Hold from Buy at TD Cowen - TheFly